San Francisco, October 17, 2018 – Recardio Inc. presented today its clinical regenerative therapy program for cardiovascular diseases at the international BIO Investor Forum 2018 in San Francisco.
After completion of the Phase 1 study with dutogliptin and confirmation of the drug’s safety Recardio has initiated a global, randomized, double-blind, placebo-controlled, safety and efficacy Phase 2 Study of dutogliptin in combination with filgrastim in early recovery post-myocardial infarction in several European Sites.
Frank Ahmann, Chief Operating Officer of Recardio, has presented the clinical development program for this indication and the therapeutic platform for the regenerative medication for patients with a range of cardiovascular diseases.
The investor forum explores investment trends and opportunities in life sciences, with a focus on venture-stage growth and emerging public companies as well as those poised to join the growth “watch list” in 2019. Because the mission is to support industry-wide success, the bio forum strives to present a broad and unbiased view of investment opportunities and companies. It is an important event for the biotechnology field and provides a great opportunity to network and partner up with other companies and delegates from this area. Recardio was invited to present itself after a selection process in the discovery companies track.
More information about the clinical program is available by visiting the following link.
Recardio Inc. is a clinical-stage life science company focusing on regenerative therapies for cardiovascular diseases. The company’s lead drug candidate, dutogliptin, is a DPP-IV inhibitor that has demonstrated significant effects in activating SDF-1, a protein that is critical for cardiac regeneration. In addition to its current Phase 2 clinical program, Recardio will fully develop the therapeutic platform as a regenerative medication for patients with various cardiovascular diseases including acute myocardial infarction and chronic heart failure, with the potential of improving heart function, quality of life and survival. For more information, visit: http://www.recardio.eu/